@article{062887cf07344b45b35212a374d922bf,
title = "Thrombin-receptor antagonist vorapaxar in acute coronary syndromes",
abstract = "Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation.",
keywords = "Acute Coronary Syndrome, Aged, Angioplasty, Cardiovascular Diseases, Combined Modality Therapy, Coronary Artery Bypass, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Hemorrhage, Humans, Intracranial Hemorrhages, Kaplan-Meier Estimate, Lactones, Male, Middle Aged, Platelet Aggregation Inhibitors, Pyridines, Receptor, PAR-1",
author = "Pierluigi Tricoci and Zhen Huang and Claes Held and Moliterno, {David J} and Armstrong, {Paul W} and {Van de Werf}, Frans and White, {Harvey D} and Aylward, {Philip E} and Lars Wallentin and Edmond Chen and Yuliya Lokhnygina and Jinglan Pei and Sergio Leonardi and Rorick, {Tyrus L} and Kilian, {Ann M} and Jennings, {Lisa H K} and Giuseppe Ambrosio and Christoph Bode and Angel Cequier and Cornel, {Jan H} and Rafael Diaz and Aycan Erkan and Kurt Huber and Hudson, {Michael P} and Lixin Jiang and Jukema, {J Wouter} and Lewis, {Basil S} and Lincoff, {A Michael} and Gilles Montalescot and Nicolau, {Jos{\'e} Carlos} and Hisao Ogawa and Matthias Pfisterer and Prieto, {Juan Carlos} and Witold Ruzyllo and Sinnaeve, {Peter R} and Storey, {Robert F} and Marco Valgimigli and Whellan, {David J} and Petr Widimsky and John Strony and Harrington, {Robert A} and Mahaffey, {Kenneth W} and {TRACER Investigators} and Rasmussen, {Lars Hvilsted}",
year = "2012",
doi = "10.1056/NEJMoa1109719",
language = "English",
volume = "366",
pages = "20--33",
journal = "The New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",
}